Gerard G. Hanna

UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy

Gerard G. Hanna, Louise Murray, R. Patel et al. · Clinical Oncology · 2017 · 274 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A. Fennell, Sean Ewings, Christian H. Ottensmeier et al. · The Lancet Oncology · 2021 · 259 citations · Full text

Medicine, Oncology, Pharmacology +15

UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy

Patricia Díez, Gerard G. Hanna, K. Aitken et al. · Clinical Oncology · 2022 · 129 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer

John Conibear, Brendan J. Chia, Yenting Ngai et al. · BMJ Open · 2018 · 77 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Improving target delineation on 4-dimensional CT scans in stage I NSCLC using a deformable registration tool

Iris E. van Dam, John R. van Sörnsen de Koste, Gerard G. Hanna et al. · Radiotherapy and Oncology · 2010 · 71 citations

Medicine, Oncology, Radiology +16